Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loratadine with Rapamune in Lymphangioleiomyomatosis
2024-516808-42-00Phase 2Completed
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sirolimus in lymphangioleiomyomatosis (LAM) (2 arms), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Incidence of adverse effects with loratadine + rapamycin. Started Sep 2024; status: completed.
02
Drugs
sirolimus
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on 2024-516808-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516808-42-00.